doi: 10.1182/asheducation-2005.1.340.
MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management
Affiliations
- PMID: 16304401
- DOI: 10.1182/asheducation-2005.1.340
Item in Clipboard
MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management
Hematology Am Soc Hematol Educ Program.
2005.
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic, pre-malignant disorders characterized by monoclonal plasma cell proliferation in the bone marrow and absence of end-organ damage. Recent advances in the pathogenesis, natural history, and prognosis of MGUS and SMM are reviewed. A new risk stratification system to determine the prognosis of MGUS using the size and type of M protein, and the serum free light chain assay is discussed.
Similar articles
-
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.Clin Cancer Res. 2011 Apr 1;17(7):1692-700. doi: 10.1158/1078-0432.CCR-10-1066. Epub 2011 Feb 16. Clin Cancer Res. 2011. PMID: 21325290
-
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Blood Rev. 2007 Sep;21(5):255-65. doi: 10.1016/j.blre.2007.01.002. Epub 2007 Mar 26. Blood Rev. 2007. PMID: 17367905 Review.
-
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.Blood. 1999 Oct 15;94(8):2583-9. Blood. 1999. PMID: 10515861
-
Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e71-7. doi: 10.1016/j.clml.2016.02.034. Epub 2016 Feb 27. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27013181
-
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22. Hematol Oncol Clin North Am. 2014. PMID: 25212882 Review.
Cited by
-
Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report.World J Clin Cases. 2022 May 16;10(14):4698-4703. doi: 10.12998/wjcc.v10.i14.4698. World J Clin Cases. 2022. PMID: 35663063 Free PMC article.
-
Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study.Clin Lymphoma Myeloma Leuk. 2023 Aug;23(8):626-632. doi: 10.1016/j.clml.2023.04.010. Epub 2023 Apr 28. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37208255 Free PMC article.
-
Clinical characteristics and outcomes in biclonal gammopathies.Am J Hematol. 2016 May;91(5):473-5. doi: 10.1002/ajh.24319. Epub 2016 Apr 6. Am J Hematol. 2016. PMID: 26840395 Free PMC article.
-
Multiple myeloma and physical activity: a scoping review.BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576. BMJ Open. 2015. PMID: 26614625 Free PMC article.
-
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691. J Manag Care Spec Pharm. 2021. PMID: 34818089 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
